Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective
- PMID: 36682521
- DOI: 10.1016/j.lfs.2023.121414
Intestinal microbiome diversity of diabetic and non-diabetic kidney disease: Current status and future perspective
Abstract
A significant portion of the health burden of diabetic kidney disease (DKD) is caused by both type 1 and type 2 diabetes which leads to morbidity and mortality globally. It is one of the most common diabetic complications characterized by loss of renal function with high prevalence, often leading to acute kidney disease (AKD). Inflammation triggered by gut microbiota is commonly associated with the development of DKD. Interactions between the gut microbiota and the host are correlated in maintaining metabolic and inflammatory homeostasis. However, the fundamental processes through which the gut microbiota affects the onset and progression of DKD are mainly unknown. In this narrative review, we summarised the potential role of the gut microbiome, their pathogenicity between diabetic and non-diabetic kidney disease (NDKD), and their impact on host immunity. A well-established association has already been seen between gut microbiota, diabetes and kidney disease. The gut-kidney interrelationship is confirmed by mounting evidence linking gut dysbiosis to DKD, however, it is still unclear what is the real cause of gut dysbiosis, the development of DKD, and its progression. In addition, we also try to distinguish novel biomarkers for early detection of DKD and the possible therapies that can be used to regulate the gut microbiota and improve the host immune response. This early detection and new therapies will help clinicians for better management of the disease and help improve patient outcomes.
Keywords: Diabetic kidney disease; Gut microbiota; Host immunity; Inflammation; Novel biomarkers.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The author declares that there are no conflicts of interest. The work described in the article has not been published previously. Its publication is approved by all authors and tacitly or explicitly by Vellore Institute of Technology (VIT), Vellore, India, and if accepted will not be published elsewhere.
Similar articles
-
The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.Int J Mol Sci. 2021 Sep 6;22(17):9641. doi: 10.3390/ijms22179641. Int J Mol Sci. 2021. PMID: 34502562 Free PMC article. Review.
-
Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.Front Immunol. 2023 Jan 19;14:1124704. doi: 10.3389/fimmu.2023.1124704. eCollection 2023. Front Immunol. 2023. PMID: 36742307 Free PMC article. Review.
-
A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals.Front Endocrinol (Lausanne). 2022 Oct 20;13:1018093. doi: 10.3389/fendo.2022.1018093. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36339429 Free PMC article.
-
Tangshen Formula alleviates inflammatory injury against aged diabetic kidney disease through modulating gut microbiota composition and related amino acid metabolism.Exp Gerontol. 2024 Apr;188:112393. doi: 10.1016/j.exger.2024.112393. Epub 2024 Mar 10. Exp Gerontol. 2024. PMID: 38458480
-
Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease.Gut Microbes. 2025 Dec;17(1):2473506. doi: 10.1080/19490976.2025.2473506. Epub 2025 Mar 6. Gut Microbes. 2025. PMID: 40050256 Free PMC article.
Cited by
-
Dietary patterns and diabetic microvascular complications risk: a Mendelian randomization study of European ancestry.Front Nutr. 2024 Nov 1;11:1429603. doi: 10.3389/fnut.2024.1429603. eCollection 2024. Front Nutr. 2024. PMID: 39555188 Free PMC article.
-
Bioinformatics analysis of the diversity of gut microbiota and different microbiota on insulin resistance in diabetes mellitus patients.Heliyon. 2023 Nov 10;9(12):e22117. doi: 10.1016/j.heliyon.2023.e22117. eCollection 2023 Dec. Heliyon. 2023. PMID: 38125495 Free PMC article.
-
Diabetic Kidney Disease: Contribution of Phenyl Sulfate Derived from Dietary Tyrosine upon Gut Microbiota Catabolism.Biomolecules. 2024 Sep 13;14(9):1153. doi: 10.3390/biom14091153. Biomolecules. 2024. PMID: 39334919 Free PMC article. Review.
-
Diphenyl diselenide protects against diabetic kidney disease through modulating gut microbiota dysbiosis in streptozotocin-induced diabetic rats.Front Pharmacol. 2024 Dec 3;15:1506398. doi: 10.3389/fphar.2024.1506398. eCollection 2024. Front Pharmacol. 2024. PMID: 39697537 Free PMC article.
-
Metabolites Potentially Derived from Gut Microbiota Associated with Podocyte, Proximal Tubule, and Renal and Cerebrovascular Endothelial Damage in Early Diabetic Kidney Disease in T2DM Patients.Metabolites. 2023 Jul 28;13(8):893. doi: 10.3390/metabo13080893. Metabolites. 2023. PMID: 37623837 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical